Study Information
Status: Active, Not Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
Palo Alto/Santa Cruz
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Multiple Sclerosis study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (or placebo) or intravenous (IV) ocrelizumab (or placebo) in a blinded fashion. Approximately 946 participants will be enrolled and will be recruited globally.
Principal Investigator
Ariele L Greenfield, M.D., Director of PAMF Multiple Sclerosis Center
Co-Investigator(s)
Minal Bhanushali, MD, PAMFRI Medical Director, David Gershfield, MD, Christine Hessler, MD
Funder
F. Hoffman-La Roche Ltd
Related Studies
Quantifying 2D and 3D MRI Imaging For Improving MS Diagnosis, Treatment, And Clinical Care
Create a longitudinal proof-of-concept MS research database (MSClinQ) that can support clinical queries, and can be updated with new tx, dx tools, care options
Investigators: Xiaowei (Sherry) Yan, PhD, MS, J.B. Jones, PhD, MBA
Using Mobile Technology and Analytics to Track Outcomes in MS Patients
Develop an app to collect and transform pt-reported outcomes in MS for health care providers to improve care and support shared decision making.
Investigators: Xiaowei (Sherry) Yan, PhD, MS, J.B. Jones, PhD, MBA
Precision Medicine for Multiple Sclerosis: Making It Work (MS-SHARE)
Develop an app that support access to clinical data and shared decision-making, predict disease course, and guide disease management.
Investigators: J.B. Jones, PhD, MBA, Xiaowei (Sherry) Yan, PhD, MS